Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell

Endocrinology

Volumn 152, Issue 12, 2011, Pages 4610-4619

  Mulherin, Andrew J ^a   Oh, Amy H ^a   Kim, Helena ^a   Grieco, Anthony ^a   Lauffer, Lina M ^a,b   Brubaker, Patricia L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; ADENYLATE KINASE; ATROPINE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GALLAMINE; GASTRIN RELEASING PEPTIDE; GLUCAGON LIKE PEPTIDE 1; METFORMIN; PIRENZEPINE; RC 3095;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CELL; L CELL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RAT; SALIVATION; VAGOTOMY; VAGUS NERVE; VAGUS NERVE STIMULATION;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; ENTEROENDOCRINE CELLS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MICE; RATS;

EID: 82355165097     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1485     Document Type: Article

References (67)

1. Mojsov S, Weir GC, Habener JF 1987 Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79:616-619 (Pubitemid 17009701)
2. Lovshin JA, Drucker DJ 2009 Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262-269
3. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S 1989 Glucagonostatic and insulinotropic action of glucagon-like peptide I-(7-36)-amide. Diabetes 38:902-905 (Pubitemid 20022397)
4. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA 1996 Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19:580-586
5. Schirra J, Katschinski M, Weidmann C, Schäfer T, Wank U, Arnold R, Göke B 1996 Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97:92-103 (Pubitemid 26021698)
6. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR 1996 A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72 (Pubitemid 26008136)
7. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, Egan JM 2000 Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:1936-1941 (Pubitemid 32274340)
8. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, Egan JM 2000 Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49:741-748 (Pubitemid 30339989)
9. Wang Q, Brubaker PL 2002 Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45:1263-1273
10. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R 2002 Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397-4408 (Pubitemid 35239574)
11. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ 1995 Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131
12. Ahrén B 2011 GLP-1 for type 2 diabetes. Exp Cell Res 317:1239-1245
13. Brubaker PL 2010 Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology 151:1984-1989
14. Parker HE, Reimann F, Gribble FM 2010 Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med 12:e1
15. Pols TW, Auwerx J, Schoonjans K 2010 Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease. Gastroenterol Clin Biol 34:270-273
16. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V 1993 Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 138:159-166 (Pubitemid 23266831)
17. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B 1995 Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56:117-126
18. Rask E, Olsson T, Söderberg S, Johnson O, Seckl J, Holst JJ, Ahrén B 2001 Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 24:1640-1645 (Pubitemid 33716463)
19. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Göke B 1992 Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22:283-291
20. Borgstrom B, Dahlqvist A, Lundh G, Sjovall J 1957 Studies of intestinal digestion and absorption in the human. J Clin Invest 36:1521-1536
21. Rocca AS, Brubaker PL 1999 Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140:1687-1694 (Pubitemid 29149238)
22. Roberge JN, Brubaker PL 1993 Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 133:233-240 (Pubitemid 23206398)
23. Roberge JN, Gronau KA, Brubaker PL 1996 Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. Endocrinology 137:2383-2388
24. Persson K, Gingerich RL, Nayak S, Wada K, Wada E, Ahrén B 2000 Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice. Am J Physiol Endocrinol Metab 279:E956-E962
25. Anini Y, Hansotia T, Brubaker PL 2002 Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. Endocrinology 143:2420-2426 (Pubitemid 34521588)
26. Balks HJ, Holst JJ, von zur Mühlen A, Brabant G 1997 Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab 82:786-790 (Pubitemid 27106588)
27. Beglinger S, Drewe J, Schirra J, Göke B, D'Amato M, Beglinger C 2010 Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion. J Clin Endocrinol Metab 95:879-886
28. Iakoubov R, Ahmed A, Lauffer LM, Bazinet RP, Brubaker PL 2011 Essential role for protein kinase Cζ in oleic acid-induced glucagon-like peptide-1 secretion in vivo in the rat. Endocrinology 152:1244-1252
29. Lauffer LM, Iakoubov R, Brubaker PL 2009 GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58:1058-1066
30. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K 2009 TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10:167-177
31. Gribble FM, Williams L, Simpson AK, Reimann F 2003 A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52:1147-1154 (Pubitemid 36523349)
32. Bosi E 2009 Metformin - the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes Obes Metab 11(Suppl 2):3-8
33. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI 2000 Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063-2069
34. Musi N, Goodyear LJ 2003 AMP-activated protein kinase and muscle glucose uptake. Acta Physiol Scand 178:337-345 (Pubitemid 36960424)
35. Sajan MP, Bandyopadhyay G, Miura A, Standaert ML, Nimal S, Longnus SL, Van Obberghen E, Hainault I, Foufelle F, Kahn R, Braun U, Leitges M, Farese RV 2010 AICAR and metformin, but not exercise, increase muscle glucose transport through AMPK-, ERK-, and PDK1-dependent activation of atypical PKC. Am J Physiol Endocrinol Metab 298:E179-E192
36. Maida A, Lamont BJ, Cao X, Drucker DJ 2011 Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 54:339-349
37. Molloy AM, Ardill J, Tomkin GH 1980 The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects. Diabetologia 19:93-96 (Pubitemid 10085869)
38. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Messeri G, Rotella CM 2001 Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 24:489-494 (Pubitemid 32198418)
39. Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S, Pezzatini A, Brogi M, Dicembrini I, Cremasco F, Messeri G, Rotella CM 2004 Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes Nutr Metab 17:336-342
40. Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FP, Flatt PR, Bell PM 2005 Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 22:654-657 (Pubitemid 40593146)
41. Cuthbertson J, Patterson S, O'Harte FP, Bell PM 2009 Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in type 2 diabetes. Diabet Med 26:649-654
42. Green BD, Irwin N, Duffy NA, Gault VA, O'harte FP, Flatt PR 2006 Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 547:192-199 (Pubitemid 44373906)
43. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I 2002 Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 298:779-784 (Pubitemid 35356808)
44. Migoya EM, Bergeron R, Miller JL, Snyder RN, Tanen M, Hilliard D, Weiss B, Larson P, Gutierrez M, Jiang G, Liu F, Pryor KA, Yao J, Zhu L, Holst JJ, Deacon C, Herman G, Thornberry N, Amatruda J, Williams-Herman D, Wagner JA, SinhaRoy R 2010 Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 88:801-808
45. Hinke SA, Kühn-Wache K, Hoffmann T, Pederson RA, McIntosh CH, Demuth HU 2002 Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 291:1302-1308 (Pubitemid 34694333)
46. Brubaker PL, Vranic M 1987 Fetal rat intestinal cells in monolayer culture: a new in vitro system to study the glucagon-like immunoreactive peptides. Endocrinology 120:1976-1985 (Pubitemid 17069231)
47. Drucker DJ, Brubaker PL 1989 Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine. Proc Natl Acad Sci USA 86:3953-3957 (Pubitemid 19154723)
48. Brubaker PL 1988 Control of glucagon-like immunoreactive peptide secretion from fetal rat intestinal cultures. Endocrinology 123:220-226
49. Drucker DJ, Jin T, Asa SL, Young TA, Brubaker PL 1994 Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Mol Endocrinol 8:1646-1655
50. Reimer RA, Darimont C, Gremlich S, Nicolas-Métral V, Rüegg UT, Macé K 2001 A human cellular model for studying the regulation of glucagon-like peptide-1 secretion. Endocrinology 142:4522-4528 (Pubitemid 32907084)
51. de Bruïne AP, Dinjens WN, van der Linden EP, Pijls MM, Moerkerk PT, Bosman FT 1993 Extracellular matrix components induce endocrine differentiation in vitro in NCI-H716 cells.AmJ Pathol 142:773-782 (Pubitemid 24063995)
52. Anini Y, Brubaker PL 2003 Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 52:252-259 (Pubitemid 36173176)
53. Marchetti P, Benzi L, Cecchetti P, Giannarelli R, Boni C, Ciociaro D, Ciccarone AM, Di Cianni G, Zappella A, Navalesi R 1987 Plasma biguanide levels are correlated with metabolic effects in diabetic patients. Clin Pharmacol Ther 41:450-454 (Pubitemid 17058931)
54. Sambol NC, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM, Benet LZ, Karam JH 1996 Pharmacokinetics and pharmaco-dynamics of metformin in healthy subjects and patients with non-insulin-dependent diabetes mellitus. J Clin Pharmacol 36:1012-1021 (Pubitemid 27014728)
55. Anini Y, Brubaker PL 2003 Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology 144:3244-3250 (Pubitemid 36819927)
56. Plaisancie P, Bernard C, Chayvialle JA, Cuber JC 1994 Regulation of glucagon-like peptide-1-(7-36) amide secretion by intestinal neurotransmitters and hormones in the isolated vascularly perfused rat colon. Endocrinology 135:2398-2403 (Pubitemid 24377394)
57. Brubaker PL 1991 Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology 128:3175-3182
58. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I 2004 Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats. J Pharmacol Exp Ther 310:614-619 (Pubitemid 38988906)
59. Lee SK, Lee JO, Kim JH, Kim SJ, You GY, Moon JW, Jung JH, Park SH, Uhm KO, Park JM, Suh PG, Kim HS 2011 Metformin sensitizes insulin signaling through AMPK-mediated pten down-regulation in preadipocyte 3T3-L1 cells. J Cell Biochem 112:1259-1267
60. Kim YW, Kim JY, Park YH, Park SY, Won KC, Choi KH, Huh JY, Moon KH 2006 Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes 55:716-724
61. Hansen L, Deacon CF, Orskov C, Holst JJ 1999 Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9- 36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356-5363
62. Pinski J, Yano T, Rekasi Z, Cai RZ, Radulovic S, Schally AV 1992 High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration. Regul Pept 41:185-193
63. Petit JM, Denoroy L, Jouvet M 1992 Effects of chronic atropine administration on regional vasoactive intestinal polypeptide concentrations in the rat brain. Eur J Pharmacol 212:79-85
64. van Waarde A, Visser GM, Visser TJ, Bouwer J, Paans AM, Vaalburg W 1994 Rodent biodistribution and metabolism of titiated 4-DAMP, a M3 subtype-selective cholinoceptor ligand. Nucl Med Biol 21:41-47 (Pubitemid 24037221)
65. Pinski J, Yano T, Schally AV 1992 Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats. Neuroendocrinology 56:831-837 (Pubitemid 23099555)
66. Chen L, Smith CD, Liu Y, McIntyre MS, Danger DP, McNulty JA, Jackson TD, Ross SA, Klein J-LD, Way JM, Nystrom CC, Croom DK, Anderson DI, Cunningham AJ, Young TA Potential gastrointestinal mechanisms for the anti-diabetic effect of metformin. Diabetes 60(S1):1795-P (Abstract)
67. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE 2007 Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30:1979-1987 (Pubitemid 47219404)